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Asthma is an increasingly prevalent chronic respiratory disease particularly affecting children. Microbial
colonization during early life has emerged as a central factor influencing asthma susceptibility. A recently
published prospective study links the reduction in relative abundance of 4 bacterial genera at 3 months of
age to the development of asthma.Numerous post-natal factors, including
mode of delivery, diet, use of antibiotics,
and the environment, have been linked
with the development of allergies and
asthma later in childhood. A common
thread between these factors is that
they all affect the composition and diver-
sity of microorganisms colonizing our
body (the microbiota). A current leading
concept is that exposure to microbes,
especially in the post-natal period, is a
key determinant of immune maturation
and protection against chronic allergic
diseases. However, fundamental ques-
tions remain: when is the critical post-
natal period during which the microbiota
has the greatest impact on the develop-
ment of disease (the so-called ‘‘window
of opportunity’’)? Through which mecha-
nisms do host-microbe interactions
shape long-term susceptibility or protec-
tion? Recent studies have started to
shed light on these questions and could
be the basis for future early childhood in-
terventions against allergies and asthma.
Early-Life Immune Maturation and
Microbiota
In children, reduced microbial diversity in
the gut during the first weeks/year of life
has been associated with increased risk
of asthma (Abrahamsson et al., 2014).
More recently, a specific upper respiratory
tract microbial profile was linked with the
development of chronic wheeze in a child
cohort (Teo et al., 2015). In this study’s
cohort, the authors identified a subgroup
(14%) of children up to 3 months old with
asymptomatic nasopharyngeal coloniza-
tion, characterized by high levels of
Streptococcus species (>20% of relative
abundance), who later developed an
increased prevalence of atopy by 2 years
and wheeze at 5 years of age. Studies
from experimental animal models haveprovided more mechanistic insights. For
example, murine experiments demon-
strated a protective effect of the intestinal
bacteria Helicobacter pylori, on allergic
airway disease (Arnold et al., 2011).
Consistent with the window-of-opportu-
nity hypothesis, neonatal mice infected
withHelicobacter pyloriwere less suscep-
tible to the disease than mice infected
at adulthood. This effect was mediated
by the induction of long-lived inducible
T regulatory cells (Tregs). Similarly, mice
treated with antibiotics early in life
(causing a disruption in the gutmicrobiota)
were more susceptible to allergic asthma
than mice treated in adulthood (Russell
et al., 2012). Again, the ability of a complex
microbial community to protect against
the development of allergy was associ-
ated with the presence of inducible Tregs.
Yet the protective effect of microbial
colonization is not limited to Tregs, as
colonization of germ-free mice within the
first 3 post-natal weeks was also reported
to prevent an exaggerated responsive-
ness of allergy-promoting invariant natural
killer T cells (Olszak et al., 2012). Similar to
the gut, the microbiota in the lung has
been shown to be critical for host immune
maturation and protection against
asthma within a critical 2-week post-natal
period (Gollwitzer et al., 2014). Again, the
protective effect was mediated by Treg
induction, via PD-L1 expression on lung
dendritic cells (DCs). Overall, both epide-
miological and experimental studies have
linked microbial exposure during early
life with protection or susceptibility to al-
lergies and asthma; however, there is as
yet no single time or microbial signature
that can predict health or disease.
The Microbiota and Metabolism
Beyond immunology, it is important to
consider the microbiota as an entity inCell Host & Microbe 18, Nitself; after all, 99% of the DNA in and on
our bodies is microbial. One major impact
of the microbiota, particularly in the gut,
is the production of metabolites. For
example, the breakdown of dietary com-
ponents by gut bacteria results in produc-
tion of short-chain fatty acids (SCFAs),
which have immunomodulatory proper-
ties. In children, differential fecal SCFA
levels at 1 year and 4 years of age have
been associated with the development
of allergy (Sandin et al., 2009). SCFAs
have also been shown to regulate immune
responses in mouse models, for example
by stimulating Tregs (Arpaia et al., 2013)
or altering hematopoiesis (Trompette
et al., 2014). An important and emerging
way to investigate microbiota function-
ality is by analyzing its global genetic con-
tent (metagenome). Metagenomics has
already been used for the study of the
gastrointestinal and airway microbiota,
but until very recently no data were avail-
able, which allowed comparison of bacte-
rial communities during early life with the
later development of allergy.
The Canadian CHILD cohort study
is one of the first human longitudinal
prospective studies seeking to assess
intestinal microbial composition and func-
tionality within the first year of life with the
development of asthma (Arrieta et al.,
2015). Arrieta et al. (2015) analyzed feces
and urine from children at 3 months and
1 year of age. Cohort subjects were
grouped in different clinical phenotypes
based upon the diagnosis of atopy (posi-
tive allergy skin prick test) and/or wheeze
(assessed by a clinician) at 1 year.
Notably, the atopy + wheeze phenotype
(14.5% of study participants) is particu-
larly relevant given its strong association
with asthma diagnosis at 3 years. Overall,
microbial composition and diversity did
not differ between the clinical phenotypesovember 11, 2015 ª2015 Elsevier Inc. 523
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Figure 1. Impact of Microbiota on Immune Maturation during the First Year of Life
Soon after birth, microbes start colonizing mucosal body surfaces. Bacterial load and diversity rapidly increases, exposing the mucosa to a variety of microbial
metabolic end products, such as short-chain fatty acids (SCFAs). Suchmolecules form themetabolic activity of a complex and dynamic microbial community, as
inferred by its metagenome. By sensing these stimuli, the immature immune system mounts specific responses promoting tolerance to allergens later in life.
Immune tone in the tissue can be set by the expansion or recruitment of cells such as regulatory T cells (Tregs) and invariant natural killer T cells (iNKT cells) during
the first post-natal weeks in mice. In humans, this ‘‘window of opportunity’’ could fall within the first few months of life. Alterations in the microbiota during this
particular time frame can influence the establishment and progression of allergic disorders, such as asthma. A better understanding of the mechanisms
underlying host-microbe interactions in early life could thus open the way for future therapeutic strategies.
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attention on a subset of low-abundance
bacteria, the authors observed a signifi-
cant reduction of the relative abundance
of 4 bacterial genera: (Faecalibacterium,
Lachnospira, Veillonella, and Rothia
[FLVR]) between the atopy + wheeze
and control groups. The differences
were significant at 3 months of age but
less pronounced at 1 year, leading to the
enticing suggestion that perhaps these
changes at 3 months of age could fall
within the predicted ‘‘window of opportu-
nity.’’ Microbial functionality was then
investigated with both metagenomic and
metabolomic approaches. Use of the
PICRUSt predictive algorithm indicated
that the metagenome of the atopy +
wheeze group was different from the
one of the control group at 3 months
of age, but not at one year. LPS biosyn-
thesis genes differed most between the
groups, consistent with differences in
direct measurements of LPS levels in524 Cell Host & Microbe 18, November 11, 20feces. In a metabolomic approach,
fecal acetate levels were found to be
significantly lower in the atopy + wheeze
group, which was not the case for other
SCFAs. Interestingly, higher acetate (and
propionate) levels have recently been
shown to be protective in a mouse model
of asthma (Trompette et al., 2014). Other
analyses of microbial-derived products
in the urine showed differences between
the groups, particularly enterohepatic
metabolites, although the significance
of these findings is unclear. In a bold
approach, Arrieta et al. (2015) attempted
to reconstitute germ-free mice with a
human gut microbiota enriched in the
low-abundance bacteria they identified
(FLVR). However, likely due to technical
and cross-species factors, the reconsti-
tuted mice could not fully establish a
human microbiota, and the immunolog-
ical effects appeared to be restricted to
neutrophils and not eosinophils as one
might have expected.15 ª2015 Elsevier Inc.Where Do These Recent Studies
Leave Us Now?
While the concept of a critical window
early in life in both human andmice is sup-
ported by multiple approaches, its exact
timing still needs to be defined. However,
this time window is likely to be tighter
than previously expected and could be
within the first few months, as opposed
to years, of life in humans. In mice, this
window is within the first 2–3 weeks of
life. Clearly, the microbiota is a major
player influencing what happens during
this window (Figure 1). The microbiota is
a complex ecosystem in itself, harboring
high diversity in terms of composition
and sometimes redundant metabolic
activities. The field still does not know
whether diversity of microbes, and thus
a likely broad representation of microbial
genes capable of maintaining a healthy
mutualism with the host, or the presence
of certain microbial species (even at a
low abundance) is more important.
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In TranslationFurther progress forward might require a
shift away from the current focus on taxo-
nomic composition of the microbiota to-
ward a more global analysis of microbial
metabolic potential. Such an approach
would allow the formulation of mecha-
nistic studies aimed at allowing the
rational design of diagnostic or interven-
tion strategies and, potentially, a reversal
of the global trends toward increased
asthma prevalence.
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